VERU INC. VERU
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
0/9
Piotroski F — financial health
-36.12
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$22.7M | — | -$30.0M | $18.3M |
| 2024 | $16.9M | -$37.8M | $5.9M | -$21.8M | $32.3M |
| 2023 | $16.3M | -$93.2M | $7.6M | -$88.7M | $19.7M |
| 2022 | $39.4M | -$83.8M | $30.6M | -$48.2M | $82.8M |
| 2021 | $61.3M | $7.4M | $47.9M | -$15.9M | $152.3M |
| 2020 | $42.6M | -$19.0M | $30.8M | -$2.0M | $30.1M |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -36.12 (distress)
- Working capital / assets 0.373
- Retained earnings / assets -10.635
- EBIT / assets -0.83
- Equity / liabilities 1.594
Source: SEC EDGAR filings · CIK 0000863894 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.